PARAMUS, N.J.--(BUSINESS WIRE)--April 29, 2010. EnzymeRx, LLC (www.enzymerx.com), a clinical-stage biotechnology company, today announced top line results from its first clinical trial of pegsitacase (formerly called Uricase-PEG 20). Pegsitacase is a pegylated uricase being developed by EnzymeRx for the treatment of refractory gout and for the management of hyperuricemia associated with tumor lysis syndrome.
